Eir Ventures launches to unlock the potential of the Nordics
Around 18 months ago, four experienced life science investors, Dr Magnus Persson, Stephan Christgau, Andreas Segerros and Amanda Hayward, came...
Focus:
-
ModernaPartnershipUndisclosed
-
SanofiLicensing Agreement$2BN
-
Emergent BiosolutionsPartnershipUndisclosed
-
GlaxoSmithKlinePartnershipUndisclosed
-
Emergent BiosolutionsPartnershipUndisclosed
-
MedivirPartnershipUndisclosed
-
KKRMergers & AcquisitionsUndisclosed
-
IntravaccLicensing AgreementUndisclosed
-
FujifilmLicensing AgreementUndisclosed
-
Takeda PharmaceuticalPartnership$900M
-
Tiziana Life SciencesPartnershipUndisclosed
-
Avalon GloboCarePartnershipUndisclosed
-
ModernaPartnershipUndisclosed
-
AbbViePartnership$377M
-
MerckPartnership$500M
-
Gilead SciencesMergers & Acquisitions$275M
-
Sarepta TherapeuticsPartnershipUndisclosed
-
SanofiPartnership$425M
-
Alpine ImmuneLicensing Agreement$805M
-
Tonix PharmaceuticalsPartnershipUndisclosed
-
Orca BioCapital Raising$192M
-
PDS BiotechnologyPartnershipUndisclosed
-
Takeda PharmaceuticalPartnership$120M
-
Takeda PharmaceuticalLicensing Agreement$278M
-
Novo NordiskMergers & Acquisitions$725M
-
MerckPartnershipUndisclosed
-
AbbViePartnership$750M
-
Panacea BiotecPartnershipUndisclosed
-
AstraZenecaLicensing AgreementUndisclosed
-
RochePartnership$140M
-
![Sarepta Codiak exosomes]()
Gene therapy innovations: Sarepta and Codiak partner on exosome therapies
-
![Sanofi; Kymera]()
Sanofi partners with Kymera in $2bn protein degrader therapies deal
-
![GSK; Medicago]()
GSK partners with Medicago to develop plant-based Covid-19 vaccine
-
![Century Empirica]()
Century acquires Empirica: treating GBM with off-the-shelf cell therapies
-
![LLamasoft drug stockpiles]()
LLamasoft Q&A: drug stockpiles and the need for advanced scenario planning
-
![Ona Series A]()
Ona’s €30m Series A round: directly targeting metastasis in cancer
Submit a deal
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
DEALS ANALYSIS
C4T raises $170m for human trials of degrader drugs
Massachusetts-based C4 Therapeutics (C4T) has closed a $150m Series B financing round led by Cobro Ventures. Other new investors that contributed to the round include, among others, Bain Capital Life...
Novo Nordisk moves further into CV diseases with Corvidia acquisition
Danish pharma company Novo Nordisk has entered a definitive agreement to acquire Massachusetts-headquartered Corvidia Therapeutics. The deal involves an upfront payment of $725m, but Corvidia could be eligible to receive...
Calliditas IPO raises $90m to support rare disease pipeline
Sweden-based biotech Calliditas Therapeutics has closed its initial public offering (IPO) on the Nasdaq global select market. The IPO involved 8,306,770 common shares priced at $19.50 each, which brings the...
Novo Ventures gives the nod to NodThera’s inflammatory disease innovations
In early June, chronic inflammatory disease-focused NodThera closed a $55m Series B financing round. This financing was led by Novo Ventures, the public and private venture arm of Novo Holdings....
Spotlight on BaseLaunch: fostering innovative start-ups in Basel
Life sciences incubator and accelerator BaseLaunch was founded three years ago to support “promising new biotech ventures move from really early academia to being able to do a Series A...
Promise of AI in drug discovery: Exscientia raises $60m in Series C round
Oxford-headquartered artificial intelligence (AI) drug discovery company Exscientia has closed a Series C funding with $60m raised. The financing was led by new Danish investor Novo Holdings. As a result...
Atea closes $215m Series D round to support Covid-19 trials
Boston-based Atea Pharmaceuticals has raised $215m in a Series D financing round. The investment was led by Bain Capital Life Sciences; other new investors that participated in the round include...
Rapid Micro Biosystems raises $120m: improving contamination testing in pharma
Massachusetts-based Rapid Micro Biosystems has closed a $120m financing round, led by the new investors Ally Bridge Group and Endeavour Vision. Existing investors, including Bain Capital Life Sciences, Longitude Capital,...
Canadian Government invests $175.6m in AbCellera’s Covid-19 response
At the beginning of May, the Government of Canada committed $175.6m in funding to Vancouver-based AbCellera Biologics, a biotech company focused on developing antibody-based drugs.
AbbVie acquires Allergan: unpicking the year-long approval process
Almost a year after the first announcement of the deal, AbbVie has completed its acquisition of Ireland-based Allergan.
DEALS NEWS
Close
Close
Close
Go Top